Progressive hepatocytic fatty infiltration in rats with prehepatic portal hypertension

Hepato-Gastroenterology

Volumn 52, Issue 62, 2005, Pages 541-546

  Alonso, M J ^a   Aller, M A ^a   Corcuera, M T ^a   Nava, M P ^a   Gomez F ^a   Angulo, A ^a   Arias, J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Hepatic steatosis; Portal hypertension; Rat

Indexed keywords

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INCLUSION; COLLATERAL CIRCULATION; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; HISTOPATHOLOGY; IMAGE ANALYSIS; LIVER ATROPHY; LIVER CELL; LIVER WEIGHT; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTAL VEIN OBSTRUCTION; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; COLLATERAL CIRCULATION; DISEASE PROGRESSION; FATTY LIVER; HYPERTENSION, PORTAL; LIGATION; LIVER; MALE; MESENTERIC VEINS; ORGAN SIZE; PORTAL VEIN; RATS; RATS, WISTAR; SPLEEN; VASCULAR DISEASES; VENOUS PRESSURE;

EID: 16344380762     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Sherlock S: The portal venous system and portal hypertension In: Sherlock S (Ed.). Diseases of the liver and biliary system. London: Blackwell Scientific Publications, 1989; pp. 151-207.
2. Chojkier M, Groszmann RJ: Measurement of portal-systemic shunting in the rat using γ-labeled microspheres. Am J Physiol 1981; 240:G37-G375.
3. Vorobioff JE, Bredfeldt JE, Groszmann RJ: Hyperdynamic splanchnic circulation in a portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244:G52-G57.
4. Bosch J, Pizcueta P, Feu F, Fernández M, García- Pagán JC: Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992; 21:1-14.
5. Lin-Ch, Yang MCM, Hou MC, et al: Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology 1996; 23:537-543.
6. Van Thiel DH, Gavaler JS, Cobb CF, McClain CJ: An evaluation of the respective roles of portosystemic shunting and portal hypertension in rats upon the production of gonadal dysfunction in cirrhosis. Gastroenterology 1983; 85:154-159.
7. Diez-Arias JA, Aller MA, Palma MD, et al: Increased duodenal mucosa infiltration by mast cells in rats with portal hypertension. Dig Surg 2001; 18:34-40.
8. Rodríguez-Fabian G, Monterde G, Dieguez B, Aller MA, Arias J: Long-term portal hypertension in the rat by triple stenosing ligation of the portal vein. An Med Int 2000; 17:137-141.
9. 4 levels in short-term prehepatic portal hypertension in rats. Dig Dis Sci 2000; 45:1865-1871.
10. Pizcueta P, Piqué JM, Fernández M, et al: Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103:1909-1915.
11. Sikuler E, Groszmann RJ: Hemodynamic studies in long and short-term portal hypertensive rats: the relation to systemic glucagon levels. Hepatology 1986; 6:414-418.
12. Koteish A, Diehl AM: Animals models of steatosis. Semin Liver Dis 2001; 21:89-104.
13. Mc Cullough AJ: Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002; 34:255-262.
14. Ludwig J, Viggiano RT, Mc Gill DB, Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experience with a hither-to unnamed disease. Mayo Clin Proc 1980; 55:334-338.
15. Brunt EM, Janney CG, Di Besceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474.
16. Angulo P, Lindor KD: Treatment of nonalcoholic fatty liver: Present and emerging therapies. Semin Liver Dis 2001; 21:81-88.
17. Garg A, Misra A: Hepatic steatosis, insulin resistance and adipose tissue disorders. J Clin Endocrinol Metabolism 2002; 87:3019.
18. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002; 122:1649.
19. Falck-Ytter Y, Younossi ZM, Marchesini G, Mc Cullough AJ: Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21:17-26.
20. Kroeger RJ, Groszmann RJ: Increased portal venous resistance hinders portal pressure reduction during the administration of β-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985; 5:97-101.
21. Sikuler E, Kravetz D, Groszmann RJ: Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985; 248:G618-G625.
22. López-Talavera JC, Merrill WW, Groszmann RJ: Tumor necrosis factor α: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108:761-767.
23. Benoit JN, Barrowhan JA, Harper SL, Kvietys PR, Granger DN: Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984; 247:G486-G493.
24. Pizcueta MP, Casamitjana R, Bosch J, Rodes J: Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. Am J Physiol 1990; 258:G191-G195.
25. Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21:27-41.
26. López-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ: Thalidomide inhibits tumor necrosis factor α, decreases nitirc oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996; 23:1616-1621.
27. Hartleb M, Michielsen PP, Dziurkowska-Marek A: The role of nitric oxide in portal hypertensive systemic and portal vascular pathology. Acta Gastroenterol Belg 1997; 60:222-232.
28. Terry CM, Clikeman JA, Hoidal JR, Callahan KS: Effect of tumor necrosis factor-α and interleukin-1α on heme-oxygenase-1 expression in human endothelial cells. Am J Pathol 1998; 274:H883-H891.
29. Wiest R, Groszmann RJ: Nitric oxide and portal hypertension: Its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19:411-426.
30. Fernández M, Lambretch RW, Bonkovski HL: Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. J Hepatol 2001; 34:812-817.
31. Durán M, Aller MA, Palma MD, et al: Increase of intestinal carbon monoxide and hepatic nitric oxide in rats with prehepatic portal hypertension. J Hepatol 2002; 36(Suppl 1):200.
32. Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343:1467-1476.
33. Diehl AM: Cytokine regulation of liver injury and repair. Immunol Rev 2000; 174:160-171.
34. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM: Obesity increases sensitivity to endotoxin liver injury: implication for pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94:2557-2562.
35. Schimpl G, Pesendorfer P, Steinwender G, Feierl G, Ratschek M, Hállwarth ME: Allopurinol reduces bacterial translocation, intestinal lipid peroxidation and neutrophil-derived myeloperoxidase activity in chronic portal hypertensive and common bile duct-ligated growing rats. Pediatr Res 1996; 40:422-428.
36. Schimpl G, Pesendorfer P, Steinwender G, Feierl G, Ratscher M, Höllwarth ME: Allopurinol and glutamine attenuate bacterial translocation in chronic portal hypertensive and common bile duct-ligated growing rats. Gut 1996; 39:48-53.
37. Schimpl G, Pesendorfer P, Steinwender G, Feierl G, Ratscher M, Höllwarth ME: The effect of vitamin C and vitamin E supplementation on bacterial translocation in chronic portal hypertensive and common bile duct-ligated rats. Eur Surg Res 1997; 29:187-194.
38. Onas G, Erickson RA, Morgan T: Effect of portal hypertension on in vivo bile acid-mediated small intestinal mucosal injury in the rat. Dig Dis Sci 1990; 35:743-748.
39. Bengmark S: Liver steatosis and liver resection. Digestion 1969; 2:304-311.
40. Rao MS, Reddy JK: Peroxisomal β-oxidation and steatohepatitis. Semin Liver Dis 2001; 21:43-55.
41. Chavin KD, Yang SQ, Lin HZ, et al: Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274:5692-5700.